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ABSTRACT
Objectives Tristetraprolin (TTP), a negative regulator of
many pro-inﬂammatory genes, is strongly expressed in
rheumatoid synovial cells. The mitogen-activated protein
kinase (MAPK) p38 pathway mediates the inactivation
of TTP via phosphorylation of two serine residues.
We wished to test the hypothesis that these
phosphorylations contribute to the development of
inﬂammatory arthritis, and that, conversely, joint
inﬂammation may be inhibited by promoting the
dephosphorylation and activation of TTP.
Methods The expression of TTP and its relationship
with MAPK p38 activity were examined in non-inﬂamed
and rheumatoid arthritis (RA) synovial tissue.
Experimental arthritis was induced in a genetically
modiﬁed mouse strain, in which endogenous TTP cannot
be phosphorylated and inactivated. In vitro and in vivo
experiments were performed to test anti-inﬂammatory
effects of compounds that activate the protein
phosphatase 2A (PP2A) and promote dephosphorylation
of TTP.
Results TTP expression was signiﬁcantly higher in RA
than non-inﬂamed synovium, detected in macrophages,
vascular endothelial cells and some ﬁbroblasts and co-
localised with MAPK p38 activation. Substitution of TTP
phosphorylation sites conferred dramatic protection
against inﬂammatory arthritis in mice. Two distinct PP2A
agonists also reduced inﬂammation and prevented bone
erosion. In vitro anti-inﬂammatory effects of PP2A
agonism were mediated by TTP activation.
Conclusions The phosphorylation state of TTP is a
critical determinant of inﬂammatory responses, and a
tractable target for novel anti-inﬂammatory treatments.
INTRODUCTION
The mitogen-activated protein kinase (MAPK) p38
signalling pathway positively regulates the expres-
sion of many inﬂammatory mediators, and is
thought to play a key role in the pathogenesis of
rheumatoid arthritis (RA).1–3 Although activation
of all four MAPK p38 isoforms (α, β, γ and δ) has
been detected in RA synovial cells,3 genetic and
pharmacological evidence suggests that MAPK
p38α is likely to be the most important contributor
to joint inﬂammation and bone erosion.1 2
Prototypical inhibitors of MAPK p38α and β were
discovered in a high-throughput screen for com-
pounds that reduced the expression of tumour
necrosis factor α (TNFα) in activated macro-
phages.4 Increasingly speciﬁc and potent inhibitors
were later generated by several pharmaceutical
companies. These compounds reduced the expres-
sion of many inﬂammatory mediators and they also
demonstrated therapeutic effects in experimental
models of RA. Therefore, they were considered
promising as disease-modifying antirheumatic
drugs,2 5 and several entered clinical trials in RA.
Yet no MAPK p38 inhibitor has received regulatory
approval, seemingly due to dose-limiting hepato-
toxicity and lack of sustained anti-inﬂammatory
efﬁcacy.6 The following questions arise: Why, con-
trary to expectation, did inhibition of MAPK p38
fail to achieve lasting therapeutic effects? How
does the MAPK p38 pathway regulate inﬂamma-
tory responses? Can our understanding of the
pathway still be leveraged to devise more effective
anti-inﬂammatory strategies?
Many of the effects of MAPK p38 on the expres-
sion of pro-inﬂammatory genes are mediated by the
mRNA-binding protein tristetraprolin (TTP). TTP
binds to adenosine/uridine-rich elements (AREs) in
the 30 untranslated regions of target mRNAs. It
then recruits deadenylases, which shorten the poly
(A) tail, resulting in suppression of translation and
rapid degradation of the mRNA.7 8 Disruption of
the mouse TTP gene (formally Zfp36) results in a
severe inﬂammatory syndrome, including an erosive
arthritis that resembles RA.8 9 Dysregulated expres-
sion of TNFα by macrophages is necessary but not
sufﬁcient for the RA-like phenotype.10 11 Either
disruption of the Zfp36 gene or targeted deletion
of the Tnf ARE renders TNF biosynthesis insensi-
tive to MAPK p38 inhibition.12 13 This indicates
that MAPK p38 enhances TNF expression by
inactivating the anti-inﬂammatory protein TTP.
Several groups have characterised the mechanism
of regulation of TTP expression and function.14–20
MAPK p38 is activated in response to various
pro-inﬂammatory stimuli, and in turn activates the
downstream kinase MAPK-activated protein kinase
2 (MK2). MK2 phosphorylates serines 52 and 178
of murine TTP (60 and 186 of human TTP).21 22
These phosphorylations have seemingly contradict-
ory effects on the expression and activity of TTP.
First, they protect it from destruction by the prote-
asome.17 18 23 Second, they inactivate it by impai-
ring its ability to recruit deadenylases,16 24 25
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reducing its afﬁnity for RNA26 or both. We recently described a
knockin mouse strain (Zfp36aa/aa), in which serine 52 and 178
codons of the endogenous Zfp36 locus were substituted by
alanine codons. These mice express a mutant form of TTP
(known as TTP-aa), which cannot be phosphorylated by MK2.
It was expressed at low levels, yet functioned as a potent sup-
pressor of many inﬂammatory mediators.15 Furthermore, the
inﬂammatory consequences of dysregulated MAPK p38 signal-
ling were mitigated by substitution of the two TTP phosphoryl-
ation sites.20
A result of the coupled stabilisation and inactivation of TTP is
that MAPK p38 activation promotes the accumulation of TTP
in its inactive form. As the activity of the MAPK p38 pathway
declines, TTP is dephosphorylated by protein phosphatase 2A
(PP2A),27 converting it to an active form that promotes degrad-
ation of target mRNAs. Because of this complex regulation of
expression and activity of TTP, acute and chronic inhibition of
MAPK p38 have very different effects on inﬂammatory mRNA
stability.28 Addition of a MAPK p38 inhibitor after a
pro-inﬂammatory stimulus causes activation of pre-existing TTP
and enhanced degradation of target mRNAs. In contrast, pro-
longed inhibition of MAPK p38 prevents the accumulation of
TTP protein, and target mRNAs consequently remain stable.
This phenomenon may contribute to the transient anti-
inﬂammatory effects of MAPK p38 inhibitors in clinical
trials.1 29 Additional mechanisms of escape from anti-
inﬂammatory effects of the inhibitors have also been sug-
gested,1 29 mostly involving the disruption of MAPK
p38-dependent negative feedback loops.
Aberrant activation of MAPK p38 signalling in the RA syno-
vium has been described.3 TTP protein has been detected in the
RA synovium,30 but the cells expressing it were not identiﬁed,
and its relationship with disease state or with MAPK p38 acti-
vity was not explored. Here, we wished to investigate whether
inactivation of TTP via the phosphorylation of serines 52 and
178 contributes to synovial inﬂammation and bone erosion, and
whether those pathological processes might be prevented by
re-activation of TTP.
METHODS
Detailed methods are provided in the online supplementary
material.
Human tissue
Synovial tissue biopsies were obtained from patients undergoing
ultrasound-guided arthroscopy. Samples were designated
‘normal’ if histological inspection revealed no macroscopic evi-
dence of inﬂammation, and absence of inﬂammatory pathology
was conﬁrmed by clinical follow-up. All participants gave
written informed consent. The study was approved by the
National Research Ethics Service Committee West Midlands.
Animal studies
All mice were maintained and housed under conventional condi-
tions in the Biomedical Services Unit at the University of
Birmingham. Experimental protocols were performed under
Home Ofﬁce guidelines and project licence 40/8003. Zfp36aa/
aa15 and TNFΔARE12 strains have been previously described.
Statistical analysis
Clinical scoring, histological analyses and scoring of bone
erosion were performed by ‘blinded’ observers. Statistical ana-
lysis was performed by Mann-Whitney U test using Prism V.6.0
(GraphPad).
RESULTS
Expression of TTP in the rheumatoid synovium
Expression of TTP protein was signiﬁcantly elevated in synovial
tissue of patients with RA compared with non-inﬂamed controls
(ﬁgure 1A, B). TTP was present in several cell types, with strongest
staining in CD68+ macrophages. The glycoproteins podoplanin
Figure 1 Expression of tristetraprolin (TTP) in the rheumatoid
synovium. Biopsies from non-inﬂamed (A, left) or rheumatoid arthritis
(RA) synovium (A, right, C-F) were stained using antibodies with the
speciﬁcities indicated, and with DAPI (4’6-diamidino-2’-phenylindole)
nuclear stain. The nuclear stain is shown only in (D), to identify the
topology of the vessel wall. Antibody isotype-matched control stains
were essentially blank (see online supplementary ﬁgure S1). (B)
Sections of non-inﬂamed or RA synovial tissue were stained with
antibody against TTP, and staining was quantiﬁed using ImageJ, by pixel
counting of three ﬁelds per section, selected and scanned in blinded
manner. *p<0.05 (Mann-Whitney U test).
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(PDPN) and CD248 are thought to identify discrete populations
of ﬁbroblasts in the rheumatoid synovium.31 There was little
co-localisation of PDPN with TTP. Instead, PDPN+ ﬁbroblasts
were interspersed with TTP+ CD68+ macrophages (ﬁgure 1C).
A subset of CD248+ cells expressed TTP (ﬁgure 1D). There was
also strong staining for TTP in CD31+ vascular endothelial cells
(ﬁgure 1E, see online supplementary ﬁgure S2). TTP protein was
co-localised with activated MK2 in the cytoplasm of many macro-
phages (ﬁgure 1F). Antibody controls and single colour images are
in online supplementary ﬁgures S1 and S2.
Blockade of TTP phosphorylation is protective in
experimental models of inﬂammation and inﬂammatory
arthritis
To test the hypothesis that phosphorylation of TTP favours joint
inﬂammation, we employed Zfp36aa/aa mice.15 Initially,
responses were tested in the zymosan-induced air pouch inﬂam-
mation model, which recapitulates aspects of the localised syn-
ovial inﬂammation observed in RA.32 Injection of zymosan into
air pouches of Zfp36+/+ mice rapidly elevated levels of CXCL1
(chemokine (C-X-C motif) ligand 1), CXCL2, interleukin (IL)-6
and TNF in the exudate ﬂuid. These cytokines are known to be
regulated by TTP,8 15 and were all underexpressed in exudate
ﬂuid of Zfp36aa/aa mice at 1 and 4 hours time points (ﬁgure
2A). In contrast, CCL5 was strongly elevated at 4 hours but not
signiﬁcantly different between Zfp36+/+ and Zfp36aa/aa mice.
Ccl5 mRNA does not possess an ARE and has not been impli-
cated as a TTP target. This result indicates that cytokine
responses are selectively rather than globally affected by the TTP
mutation. Zymosan also promoted an inﬂux of leucocytes (ﬁgure
2B), the majority of which were neutrophils (data not shown).
Cellular inﬁltration was decreased by 50% in Zfp36aa/aa mice.
Serum transfer-induced arthritis (STIA)33 was attempted next.
All Zfp36+/+ mice developed arthritis after injection of arthri-
togenic K/BxN serum (ﬁgure 3A), with transient weight loss
(ﬁgure 3B) and swelling of ankles and footpads (ﬁgure 3C).
STIA was associated with increased numbers of CD45− cells in
knee joints due to stromal cell proliferation (ﬁgure 3D); marked
inﬁltration of CD45+ cells, the majority of which were neutro-
phils and macrophages (ﬁgure 3D) and elevated expression of
the pro-inﬂammatory mRNAs Il1b, Il6, Cxcl1 and Cxcl2
(ﬁgure 3E). These changes were absent or almost absent from
serum-injected Zfp36aa/aa mice.
In Zfp36+/+ mice, K/BxN serum induced leucocytic inﬁltra-
tion of joints and skin, synovial hyperplasia and pannus forma-
tion (ﬁgure 4A), loss of articular cartilage (ﬁgure 4A, B) and
peri-articular erosion of bone (ﬁgure 4A, C), which was
accompanied by osteoclast activation (ﬁgure 4D, E). None of
these changes occurred in Zfp36aa/aa mice. Similar experiments
have been carried out four times, using three batches of K/BxN
serum from two laboratories. Disease penetrance (proportion of
mice developing a clinical score >1 for more than three con-
secutive days) was 100% in Zfp36+/+ mice and 0% in
Zfp36aa/aa mice. Cumulative disease severity, calculated as area
under the curve (AUC) of the plot of disease score against time,
was reduced by 70% in heterozygous Zfp36+/aa mice (AUC of
37.6±14.1, compared with 123.8±7.4 in Zfp36+/+ mice,
p<0.01). This ﬁnding is consistent with the dominant anti-
inﬂammatory function of the constitutively active form of
TTP,15 and suggests that a moderate alteration in the equilibrium
between phosphorylated and unphosphorylated TTP has anti-
inﬂammatory consequences.
Roles of stromal and haematopoietic TTP in protection
against experimental arthritis
To investigate the functions of TTP in haematopoietic and non-
haematopoietic compartments, bone marrow chimaeras were
generated between Zfp36+/+ and Zfp36aa/aa mice, and STIA
experiments performed. On average, 97% of CD45+ cells in
both chimaeras were donor-derived (ﬁgure 5A). In Zfp36+/+
mice, STIA developed and resolved over 26 days, while there
was no evidence of disease in Zfp36aa/aa mice over the same
interval (ﬁgure 5B). Despite subtle differences in the timings of
disease onset and resolution (ﬁgure 5B), neither mice expressing
TTP-aa in haematopoietic cells (ﬁlled grey symbols) nor in non-
haematopoietic cells (open grey symbols) were protected from
STIA, at least at the level of macroscopic symptoms (ﬁgure 5C).
However, the presence of TTP-aa in haematopoietic cells con-
ferred protection against bone erosion (ﬁgure 5D, right panels
of ﬁgure 5E).
The lack of protection from STIA in mice expressing TTP-aa
only in the haematopoietic compartment implied that TTP may
function in non-haematopoietic cells to inhibit inﬂammation.
Joint stromal cells were isolated from Zfp36+/+ and Zfp36aa/
aa mice and challenged with either IL-1β or lipopolysaccharide
(LPS; ﬁgure 5F). The expression of IL-6, CXCL1 and CXCL2
was signiﬁcantly decreased in Zfp36aa/aa stromal cells stimu-
lated with either IL-1β or LPS, except in the case of
IL-1β-stimulated CXCL1, where the difference of expression
did not achieve statistical signiﬁcance (p=0.06).
Therapeutic targeting of TTP phosphorylation
To investigate whether pharmacological disturbance of the equi-
librium between phosphorylation and dephosphorylation of
Figure 2 Zfp36aa/aa mice are protected from zymosan-induced local inﬂammation. Dorsal air pouches were created and localised inﬂammation
was induced by injection of 7 μL of 1 mg/mL zymosan. After 1 or 4 hours mice were humanely culled. (A) Cytokines and chemokines were measured
in air pouch exudate ﬂuid. Graphs represent means±SEM from 6 mice (1 hour) or 12 mice (4 hours) of each genotype. Basal expression of all
cytokines and chemokines was negligible in untreated mice (data not shown). (B) Cells in exudate ﬂuid were counted using a haemocytometer. n.s.,
not statistically signiﬁcant; *p<0.05; **p<0.01; ***p<0.005 (Mann-Whitney U test).
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Figure 3 Zfp36aa/aa mice are resistant to experimental arthritis. Zfp36+/+ and Zfp36aa/aa mice were injected intraperitoneal with 75 μL of
arthritogenic serum from K/BxN donor mice on days 0 and 1. (A) Clinical score and (B) weight were monitored over 10 days. (C) Ankle and foot pad
thickness were measured. Graphs represent mean±SEM (n=6). (D) Feet were digested at d0 or d10, CD45− and CD45+ cells, neutrophils and
macrophages were counted using ﬂow cytometry. Graphs represent mean±SEM (n=6). n.s., not statistically signiﬁcant; *p<0.05; **p<0.01;
***p<0.005 (Mann-Whitney U test). (E) At d10, RNA was recovered from digested wrist joints of three mice of each genotype, and selected
cytokine and chemokine mRNAs were measured by quantitative PCR, with normalisation ﬁrst against Gapdh then against paws of vehicle-treated,
uninﬂamed Zfp36+/+ mice. Graphs represent mean±SEM (n=3). *p<0.05; **p<0.01; ***p<0.005 (Mann-Whitney U test).
Figure 4 Zfp36aa/aa mice are resistant to experimental arthritis. Experimental arthritis was induced as in ﬁgure 3. (A) Representative H&E stained
sagittal sections of Zfp36+/+ and Zfp36aa/aa heel regions at d10. The inset boxes in upper panels are shown at higher resolution in lower panels.
C, cartilage; S, synovium; M, bone marrow; Ta, talus; Ti, tibia; *, enthesitis. (B) Similar sections were stained with fast green and Safranin O to
identify articular cartilage (red stain). Representative images are shown. (C) Whole feet were subjected to μCT. Representative images are shown
from top and side. (D) Activated osteoclasts were visualised by staining for tartrate-resistant acid phosphatase (TRAP; dark red stain) and (E)
TRAP-positive cells per heel section were counted. The graph represents mean±SEM (n=6). **p<0.01 (Mann-Whitney U test).
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TTP conferred protection against STIA, we used two chemically
distinct compounds reported to activate PP2A by disrupting its
interactions with inhibitory protein complexes.34 35 COG1410,
an apolipoprotein E peptide mimetic, exerts protective effects
in experimental models of neuroinﬂammation.36 37 AAL(s) is a
lipid derivative of the immunosuppressant FTY720 (ﬁngolimod).
Unlike its parent compound, it does not inﬂuence sphingosine 1
phosphate signalling and has no effects on lymphocyte trafﬁck-
ing. Instead, its anti-inﬂammatory effects have been attributed to
activation of PP2A and subsequently TTP.35 38 39
C57BL/6 mice were treated with vehicle, COG1410 or AAL
(s) from day 2 after the injection of K/BxN serum. Both
COG1410 and AAL(s) reduced disease progression (ﬁgure 6A),
cumulative disease severity (ﬁgure 6B) and ankle swelling
(ﬁgure 6C). AAL(s) signiﬁcantly decreased the expression of the
pro-inﬂammatory genes Il6 and Cxcl2 in joints (ﬁgure 6D). This
effect did not reach statistical signiﬁcance in COG1410-treated
mice. Βoth PP2A agonists protected against bone erosion (ﬁgure
6E). A control scrambled peptide with the same amino acid
composition as COG1410 had no effect on disease progression
(see online supplementary ﬁgure S3).
In vitro experiments investigating the mechanisms of response
to PP2A agonism employed COG1410, which had stronger anti-
inﬂammatory effects in vivo. COG1410 signiﬁcantly decreased
expression of TNF by Zfp36+/+ bone marrow-derived
macrophages (BMMs), whereas in Zfp36aa/aa BMMs the
expression of TNF was comparatively low, and was not further
decreased by COG1410 (ﬁgure 6F). COG1410 decreased the
expression of wild-type TTP, but did not affect the weak expres-
sion of TTP-aa (ﬁgure 6G). These observations support the
hypothesis that activation of PP2A and dephosphorylation of
serines 52 and 178 both activates and destabilises TTP. Effects
of COG1410 were also tested in BMMs derived from Tnf-Δare
mice, in which the TTP binding site is speciﬁcally deleted from
Tnf mRNA.12 Elevated expression of TNF in Tnf-Δare BMMs
was insensitive to COG1410, whereas the expression of CXCL2
remained sensitive to COG1410 (ﬁgure 6H). COG1410 did not
inﬂuence Akt, extracellular signal-regulated kinase (ERK),
MAPK p38 or MK2 phosphorylation in response to LPS (ﬁgure
6I). Therefore, in vitro anti-inﬂammatory effects of COG1410
require an intact TTP binding site within the target mRNA,
depend on the ability to modulate TTP phosphorylation state,
but do not involve impairment of signalling events upstream of
TTP phophorylation. In three independently derived RA syn-
ovial ﬁbroblast lines, COG1410 dose-dependently inhibited
TNF-induced IL-8 expression (ﬁgure 6J). In human monocyte-
derived macrophages, COG1410 also decreased the
LPS-induced expression of TNF (ﬁgure 6K), suggesting that
promotion of the dephosphorylation and activation of TTP may
also exert anti-inﬂammatory effects in these cells.
Figure 5 Enhanced tristetraprolin (TTP) function in both haematopoietic and non-haematopoietic compartments is required for protection against
experimental arthritis. Bone marrow chimaeras were created between Zfp36+/+ and Zfp36aa/aa mice. (A) 8 weeks after reconstitution of lethally
irradiated recipient mice, chimerism of haematopoietic cells was assessed by ﬂow cytometry of CD45.1 and CD45.2 markers. (B) Arthritis was
induced as in ﬁgure 3, and clinical scores were monitored over 26 days. (C) Cumulative disease severity was calculated for each individual mouse as
area under curve (AUC) of the plot of clinical score against time. Graph represents mean±SEM (n=3 for Zfp36+/+ and Zfp36aa/aa, n=4 for
chimaeras. n.s., not statistically signiﬁcant; ***p<0.005. (D) Bone erosion was quantiﬁed in Zfp36+/+, Zfp36aa/aa and chimeric mice.
(E) Representative μCT images of mice at d26. (F) Joints of healthy Zfp36+/+ and Zfp36aa/aa mice were digested and adherent cells passaged three
times, after which fewer than 2% of cells were CD45+. Cells were then left untreated or stimulated with 10 ng/mL interleukin (IL)-1β (upper) or LPS
(lower) for 4 hours. Secreted CXCL1, CXCL2 and IL-6 were measured. Graphs represent mean±SEM (n=3). *p<0.05; **p<0.01; ***p<0.005
(Mann-Whitney U test).
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Figure 6 Therapeutic targeting of tristetraprolin (TTP) phosphorylation. Arthritis was induced in wild-type mice by injection of K/BxN serum as in
ﬁgure 3. From d2 mice were treated daily with vehicle or COG1410 (upper panels), vehicle or AAL(s) (lower panels). Control mice were injected with
vehicle (dimethyl sulfoxide in the case of AAL(s), phosphate-buffered saline in the case of COG1410. (A) Clinical score was monitored over 8 days.
(B) Cumulative disease severity was calculated as in ﬁgure 5. (C) Right ankle thickness was measured. (D) At the end of the experiment, RNA was
isolated from wrist joints, Cxcl2 and Il6 mRNAs were measured by quantitative PCR with normalisation ﬁrst against Gapdh then against
vehicle-treated control. Graphs represent means±SEM of four mice in each treatment group. n.s., not signiﬁcant; *p<0.05; ***p<0.005
(Mann-Whitney U test). (E) Representative μCT images of ankles of mice treated to day 8 with vehicle, COG1410 or AAL(s). Bone erosion was scored
in blinded manner by three independent observers. Graphs show means±SEM. *p<0.05 (Mann-Whitney U test). (F) Zfp36+/+ and Zfp36aa/aa BMMs
were treated with LPS for 8 hours with or without 10 μM COG1410 (COG). Secreted tumour necrosis factor (TNF) was measured by ELISA. Graph
represents mean±SEM from three independent BMM isolates of each genotype. n.s., not signiﬁcant; *p<0.05 (Mann-Whitney U test). (G) Whole cell
lysates were prepared from Zfp36+/+ and Zfp36aa/aa BMMs treated as indicated, and TTP detected by western blotting. Protein abundance was
estimated by scanning densitometry, with normalisation against the loading control actin. The graph represents mean±SEM from three independent
experiments. n.s., not signiﬁcant; ***p<0.005 (Mann-Whitney U test). (H) Litter-mate control and TnfΔARE BMMs were treated with LPS for 8 hours
with or without 10 μM COG1410 (COG). Secreted TNF and CXCL2 were measured by ELISA. Graphs represents mean±SEM from three independent
BMM isolates of each genotype. n.s., not signiﬁcant; *p<0.05 (Mann-Whitney U test). (I) Zfp36+/+ BMMs were treated with LPS for 0–4 hours with
or without 10 μM COG1410 (COG). Whole cell lysates were western blotted for phosphorylated forms of Akt, ERK, mitogen-activated protein kinase
(MAPK) p38 and MK2, and for actin as a loading control. Representative of two independent experiments. ( J) Rheumatoid arthritis (RA) synovial
ﬁbroblasts were stimulated for 8 hours with 1 ng/mL TNF in the presence of 0, 1 or 2.5 μg/mL COG1410. Secreted IL-8 was measured by ELISA.
Circles, squares and triangles represent independent RA synovial ﬁbroblast cultures derived from three different patients. Each individual symbol
represents the mean of triplicate measurements. n.s., not signiﬁcant; *p<0.05 (two-way analysis of variance). (K) Monocyte-derived macrophages
were isolated from three volunteers and stimulated with LPS for 8 hours with or without 10 μM COG1410 (COG). Secreted TNF was measured
by ELISA.
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DISCUSSION
Here and elsewhere,30 40 the anti-inﬂammatory effector protein
TTP has been shown to be strongly expressed at sites of active
inﬂammation, including RA synovial lining cells. This prompted
the question of “Why TTP is not acting to reduce TNFα expres-
sion in rheumatoid synovial macrophages”.30 A likely answer is
that aberrant activation of MAPK p38 in the RA synovium leads
to the accumulation of TTP in a phosphorylated and inactive
form, so that it is incapable of downregulating TNFα and other
targets. This conclusion is based on the observations that: (1)
TTP expression was higher in inﬂamed than non-inﬂamed
synovial tissue (ﬁgure 1A, B); (2) strong expression coincided
with activation of the MAPK p38 pathway (ﬁgure 1F); (3)
precise, genetically mediated blockade of MAPK p38-dependent
phosphorylation of TTP powerfully protected mice against ex-
perimental arthritis (ﬁgures 3–5). The dramatic, inﬂammation-
resistant phenotype of the genetically modiﬁed Zfp36aa/aa
mouse in this robust experimental model is, to our knowledge,
unprecedented for such a small genetic alteration (substitution of
two codons).
Bone marrow chimaera experiments demonstrated that
protection from experimental arthritis was dependent on
enhanced function of TTP in both haematopoietic and non-
haematopoietic compartments (ﬁgure 5). This ﬁnding is con-
sistent with reports that global Zfp36 gene disruption led to spon-
taneous inﬂammatory arthritis,9 whereas myeloid-speciﬁc Zfp36
gene disruption did not.10 11 It was recently shown that TTP
negatively regulates expression of several inﬂammatory mediators
in murine embryonic ﬁbroblasts.41 Here, we show that murine
joint ﬁbroblasts containing the constitutively active form of TTP
expressed lower amounts of IL-6, CXCL1 and CXCL2 in
response to inﬂammatory stimuli. These attenuated responses of
stromal cells may help to explain the delay in onset of arthritis in
chimaeras expressing TTP-aa in their non-haematopoietic com-
partment. TTP protein was detected in a subset of synovial ﬁbro-
blasts of patients with RA (ﬁgure 1). Therefore, it is likely that
TTP functions as a suppressor of inﬂammation in at least some
joint ﬁbroblasts. The strong expression of TTP protein in vascular
endothelial cells was also striking, and may point to a role in
restraint of vascular activation, via downregulation of cytokines,
chemokines and/or adhesion molecules.40 42 43
The bone marrow chimaera experiments also revealed
uncoupling between joint inﬂammation and bone erosion
(ﬁgure 4). When TTP-aa was present in haematopoietic cells,
mice were not protected from macroscopic inﬂammation, but
were strongly protected against bone erosion. Inﬂammatory
osteolysis is dependent on MAPK p38.44 Osteoclast activation
and bone erosion were increased in mice lacking the dual speci-
ﬁcity phosphatase DUSP1, and therefore having dysregulated
MAPK p38 activity.45 In vivo delivery of TTP using an adeno-
viral vector conferred protection against experimentally induced
osteolysis.44 46 It is therefore likely that the MAPK p38-TTP
pathway controls the differentiation and/or activation of osteo-
clasts. The absence of a bone phenotype of Zfp36aa/aa mice
under resting conditions suggests that such a role would likely
be restricted to inﬂammatory contexts.
We suggest that promoting the dephosphorylation of TTP
represents a novel strategy for treatment of chronic inﬂamma-
tory pathologies such as RA. Potential advantages of this
approach are: (1) that it may avoid some of the pitfalls of target-
ing upstream signalling events; (2) that it requires no assump-
tions about the factors that drive inﬂammation or the signalling
pathways actually responsible for the phosphorylation and
inactivation of TTP in the RA synovium; (3) that it capitalises
on the accumulation of TTP at sites of inﬂammation,30 40 a
pool of dormant anti-inﬂammatory effector protein that is ripe
for re-activation. This is in keeping with the philosophy of har-
nessing edogenous off-switches and anti-inﬂammatory mecha-
nisms, rather than targeting the activators of inﬂammation.47
Proof of principle is provided by two chemically distinct com-
pounds that are reported to activate PP2A, and which reduce
inﬂammation and bone erosion in an experimental model of RA
(ﬁgure 6A–E). PP2A is a pleiotropic enzyme complex with mul-
tiple substrate phospho-proteins and cellular functions,48 there-
fore, the mechanism of anti-inﬂammatory action of PP2A
agonists is open to question. Our in vitro data support the
concept that activation of PP2A exerts anti-inﬂammatory effects
at least in part via the activation of TTP (ﬁgure 6F–I). Future
studies will investigate relationships between TTP expression
and phosphorylation state, disease activity and response to
therapy. More also needs to be known about mechanisms of rec-
ognition and dephosphorylation of TTP by PP2A. The data
reported here suggest that these will be fruitful areas to explore.
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